STAT+: Novartis picks up experimental breast cancer drug for $2B
STAT [Unofficial]
March 20, 2026
Looking to bolster its pipeline, Novartis is buying a breast cancer drug candidate for $2 billion from Delaware-based Synnovation Therapeutics.
Discussion in the ATmosphere